PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-12.41%
Negative revenue growth while Biotechnology median is 0.00%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-12.41%
Negative gross profit growth while Biotechnology median is 0.00%. Seth Klarman would suspect poor product pricing or inefficient production.
-27.47%
Negative EBIT growth while Biotechnology median is -2.44%. Seth Klarman would check if external or internal factors caused the decline.
-27.47%
Negative operating income growth while Biotechnology median is -3.11%. Seth Klarman would check if structural or cyclical issues are at play.
-27.92%
Negative net income growth while Biotechnology median is -2.11%. Seth Klarman would investigate factors dragging net income down.
-20.00%
Negative EPS growth while Biotechnology median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-20.00%
Negative diluted EPS growth while Biotechnology median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
6.47%
Share growth above Biotechnology median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
6.47%
Diluted share growth above 2x Biotechnology median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-21.90%
Negative OCF growth while Biotechnology median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-21.77%
Negative FCF growth while Biotechnology median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2645.13%
Negative 10Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
92.60%
OCF/share CAGR of 92.60% while Biotechnology median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
85.56%
3Y OCF/share growth of 85.56% while Biotechnology median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-3055.33%
Negative 10Y net income/share CAGR vs. Biotechnology median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
92.82%
Net income/share CAGR of 92.82% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
82.14%
3Y net income/share CAGR of 82.14% while Biotechnology median is zero. Walter Schloss might see a small advantage that can be scaled further.
1796.75%
Equity/share CAGR of 1796.75% while Biotechnology median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
-58.41%
Negative 5Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
18.52%
3Y equity/share CAGR of 18.52% while Biotechnology median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.03%
We expand assets while Biotechnology is negative. Peter Lynch sees a possible advantage if expansions align with profitable markets or a recovering cycle.
-6.32%
Negative BV/share change while Biotechnology median is -5.98%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-20.42%
Debt is shrinking while Biotechnology median is rising. Seth Klarman might see an advantage if growth remains possible.
29.66%
R&D growth far exceeding Biotechnology median. Jim Chanos suspects a potential “throw money at problems” approach or a race for new tech that might not pay off.
16.61%
SG&A growth far above Biotechnology median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.